Do Not Taper Dapagliflozin or Sacubitril/Valsartan When Ejection Fraction Improves
Patients whose LVEF improves to >40% should continue all HFrEF therapies—including dapagliflozin and sacubitril/valsartan—indefinitely at their current doses, as discontinuation raises the risk of recurrent LV dysfunction and adverse outcomes. 1
Core Principle: Continue GDMT Regardless of EF Recovery
The 2022 AHA/ACC/HFSA guidelines explicitly state that guideline-directed medical therapy should not be withdrawn when ejection fraction improves 1. This recommendation is based on the understanding that:
- EF improvement reflects the therapeutic effect of GDMT rather than disease resolution 2, 3
- Withdrawal of therapy leads to loss of reverse remodeling benefits 1
- The medications continue to provide mortality and morbidity reduction even after EF normalization 4
Evidence for Continuing Sacubitril/Valsartan
Reverse Remodeling Is Dose-Dependent and Ongoing
- Sacubitril/valsartan induces significant reverse cardiac remodeling within 6 months, with median absolute LVEF improvements of 8.7–10.2% across all dose ranges 5
- 40% of patients with improved EF would no longer meet ICD criteria after 6 months of therapy, demonstrating substantial structural improvement 2
- Higher doses (97/103 mg twice daily) are associated with greater NT-proBNP reduction (−667.24 pg/mL; 95% CI −1312.69 to −21.8; p=0.04), indicating superior neurohormonal modulation 6
- Baseline LVEF >30% predicts greater absolute improvement (OR 8.62; 95% CI 4.69–15.82; p=0.001), but all patients benefit from continued therapy 7
Maintaining Target Doses Is Critical
The FDA label specifies that the target maintenance dose is 97/103 mg twice daily, with dose escalation every 2–4 weeks as tolerated 8. The Canadian Cardiovascular Society emphasizes that if doses are temporarily reduced due to adverse effects, the previous tolerated dose should be resumed as soon as safely possible 9.
Key principle: Asymptomatic vital-sign changes (including improved blood pressure from better cardiac function) should not trigger dose reduction 4. Only symptomatic hypotension, orthostatic symptoms, or clinically significant hyperkalemia/renal dysfunction warrant adjustment 9.
Evidence for Continuing Dapagliflozin
SGLT2 Inhibitors Provide Benefits Beyond EF Improvement
- Dapagliflozin at 10 mg daily produces a 26% relative risk reduction in cardiovascular death or HF hospitalization regardless of baseline EF 1
- Clinical benefits begin within 30 days and are maintained long-term 10
- The drug has minimal blood-pressure-lowering effect (≈2 mmHg), making it safe even in patients with improved hemodynamics 1
- 47% of patients achieve additional reverse remodeling targets (ΔEDV <−10%, ΔESV <−15%, or ΔEF >10%) at 6 months, with associated reductions in LV filling pressures from 26% to 3% 11
Dosing Remains Fixed at 10 mg Daily
The ADA/KDIGO consensus states that dapagliflozin 10 mg daily should be continued for kidney and cardiovascular benefit until dialysis, even when eGFR falls below 25 mL/min/1.73 m² 12. There is no indication to reduce the dose when EF improves—the standard dose is 10 mg daily regardless of clinical response 12, 1.
Practical Management Algorithm
Step 1: Confirm EF Improvement
- Reassess LVEF every 1–5 years or with clinical status change 13
- Document improvement with repeat echocardiography at 6 and 12 months after GDMT optimization 2, 3
Step 2: Maintain Current GDMT Doses
- Continue dapagliflozin 10 mg daily without adjustment 12, 1
- Continue sacubitril/valsartan at the highest tolerated dose (ideally 97/103 mg twice daily) 8
- Do not reduce doses based solely on EF improvement 1
Step 3: Adjust Only for Symptomatic Adverse Effects
- Symptomatic hypotension: Separate medication timing, reduce diuretics first, then consider halving the sacubitril/valsartan dose temporarily 9, 13
- Asymptomatic hypotension or BP increase from improved cardiac function: No dose adjustment needed 4
- Hyperkalemia (K⁺ 5.6–5.9 mmol/L): Reduce MRA dose; sacubitril/valsartan and dapagliflozin typically do not require adjustment 1
Step 4: Uptitrate If Below Target
- If sacubitril/valsartan is below 97/103 mg twice daily, attempt uptitration every 2–4 weeks 8
- Improved EF often reflects better hemodynamic tolerance, making uptitration more feasible, not less 4
Common Pitfalls to Avoid
Pitfall 1: Assuming EF Recovery Means Disease Resolution
Reality: EF improvement is a treatment effect, not a cure 2, 3. Discontinuation leads to recurrent dysfunction 1.
Pitfall 2: Reducing Doses to "Lighten the Medication Burden"
Reality: The mortality benefits of GDMT are dose-dependent and require maintenance of target doses 9, 1. Sub-target dosing has not been shown to prolong life 1.
Pitfall 3: Stopping Therapy When EF Normalizes to >50%
Reality: Even patients with recovered EF (>40%) should continue all four GDMT pillars indefinitely 1. The 2025 HFA consensus reinforces that low BP from improved cardiac function should not hinder GDMT optimization 4.
Pitfall 4: Prioritizing Diuretic Reduction Over GDMT Maintenance
Reality: If symptomatic hypotension occurs, reduce or discontinue diuretics first (which lack mortality benefit), before adjusting sacubitril/valsartan or other GDMT agents 9, 13.
Special Considerations
Patients with Very High Baseline EF Improvement
- Those with baseline LVEF 31–45% experience the greatest absolute improvement (7.2% and 4.2% respectively) 7
- This does not justify dose reduction; it confirms the drugs are working as intended 5, 7
Patients No Longer Meeting ICD Criteria
- Approximately 25% of patients may no longer qualify for primary-prevention ICD after 6 months of sacubitril/valsartan 3
- This reflects successful reverse remodeling but does not change the indication for continued GDMT 2, 3